+91-8668442535
Home / Biotechnology / Bone Marro

Bone Marrow Transplantation Market By Type (Allogeneic Bone Marrow Transplant, Autologous Bone Marrow Transplant), By Indication (Leukemia, Lymphoma, Myeloma and Others) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Industry Outlook

The bone marrow transplantation market is expected to grow from US$ 8,356.4 million in 2017 to US$ 13,903.1 million by 2026, exhibiting straightforward growth at a compound annual growth rate (CAGR) of 5.9% from 2018 to 2026. According to the research findings provided by Bristol-Myers Squibb Company, by 2040, there will be 1.85 million new cases of blood cancer reported worldwide.

Market Synopsis

Lowering the risk of disease recurrence and a significant increase in the number of healthy donors are driving the growth of the allogeneic bone marrow transplant market.

Allogeneic bone marrow transplants are currently dominating the type segment of the bone marrow transplantation market. The graft is free from contaminating tumor cells, and the immunocompetent cells derived from a healthy donor may produce an immune graft versus malignancy effect. A significant rise in the number of healthy donors and a lower risk of disease recurrence together drive the allogeneic bone marrow transplant market. Autologous bone marrow transplant will be capturing the market in the near future owing to the increasing number of stem cell banks that store healthy cells from patients and, after conditioning treatment, are introduced into the patient to produce healthy blood cells.

The lymphoma indication market is growing due to an increase in the number of new cases of Hodgkin lymphoma patients and improved survival rates following bone marrow transplantation.

Lymphoma is currently reigning as the indication segment for the bone marrow transplantation market. It is of two types: Hodgkin lymphoma and non-Hodgkin lymphoma. The National Cancer Institute (NCI) reported 83,180 new cases of lymphoma in 2018. A significant rise in lymphoma patients and better survival rates post-bone marrow transplantation drive the lymphoma indications market's growth. Leukemia is the abnormal production of white blood cells in the bone marrow. The National Cancer Institute (NCI) reported 60,300 new cases of leukemia in 2018.

In North America, market growth is being driven by the rising prevalence of chronic lymphocytic leukemia and the presence of sophisticated healthcare infrastructure.

In the present scenario, North America, with a revenue share of 38%, is the clear leader in the bone marrow transplantation market. The chief parameters contributing to its market success are the rising prevalence of chronic lymphocytic leukemia. According to American Cancer Society (ACS) research findings in 2019, it is estimated that approximately 20,720 new cases of chronic lymphocytic leukemia will be reported in North America. The prevalence rate is slightly higher in men in comparison to women. The presence of sophisticated healthcare infrastructure further consolidates market growth in the North American region.

Due to the increasing number of patients suffering from multiple myeloma, Europe is in second place, accounting for 32% of the market share. As per the latest report provided by Myeloma Patients Europe (MPE), by 2025, the number of patients suffering from multiple myeloma will be around 46,000. The domicile of major players such as Lonza Group Ltd., Merck Millipore Corporation, and PromoCell GmbH further bolsters market growth in Europe. Currently, Asia Pacific holds 20% of the market share on account of proactive government policies to curb the mortality rate associated with blood cancer and technological advancements in the bone marrow transplantation technique.

Periods of History and Forecast

This research report presents the analysis of each segment from 2016 to 2026, considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

The market is segmented by type, indication, and geography.

Biotechnology firms actively engaged in bone marrow transplantation procedures are AllCells LLC, Conversant Bio, Cellular Dynamics International, Gamida Cell Ltd., Hemacare Corporation, Lonza Group Ltd., Merck Millipore Corporation, Mesoblast Ltd., PromoCell GmbH, STEMCELL Technologies.

Key questions are answered in this report.

  • Which biopharmaceutical companies are active in the bone marrow transplantation market?
  • What will be the SWOT analysis of the bone marrow transplantation market?
  • What are the prevalence rate and clinical manifestations of leukemia, lymphoma, myeloma, and other blood disorders?
  • What is the global incidence rate for lymphoma, and what is the survival rate post-bone marrow transplantation?
  • What is the difference between allogeneic and autologous bone marrow transplantation, and how do they differ in terms of patient clinical manifestations?
  • What will the market size and CAGR be for developing countries in the Asia Pacific, the Middle East, Africa, and Latin America? 

Frequently Asked Questions:

The market for Bone Marrow Transplantation Market is expected to reach US$ 13,903.1 Mn by 2026.

The Bone Marrow Transplantation Market is expected to see significant CAGR growth over the coming years, at 5.9%.

The report is forecasted from 2018-2026.

The base year of this report is 2017.

Conversant Bio, Cellular Dynamics International, Gamida Cell Ltd., Hemacare Corporation, Lonza Group Ltd., Merck Millipore Corporation, Mesoblast Ltd are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Apr 2019
Category:  Biotechnology
Report ID:   59660
Report Format:   PDF
Pages:   120
Rating:    4.2 (56)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support